---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-098042"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2026-09-08T20:10:14+00:00"
generated_at: "2026-09-08T20:11:34.509970+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Nektar enters quiet period ahead of Phase 2b REZOLVE-AA follow-up data

## Summary
- Quiet period begins September 8, 2026 until 24-week off-treatment follow-up data from Phase 2b REZOLVE-AA study is announced.
- Study evaluates rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.
- Quiet period is consistent with prior quiet periods for Phase 2b REZOLVE studies and planned data disclosures.
- No financial or operational results disclosed in this filing.

## SEC filing metadata
- accession: 0001213900-26-098042
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2026-09-08T20:10:14+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390026098042/0001213900-26-098042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390026098042/ea0304798-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-098042
- JSON: https://secwatch.observer/filing/0001213900-26-098042.json
- Plain text: https://secwatch.observer/filing/0001213900-26-098042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.